CXCR3 Signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Jenkins, Molly H ^a   Brinckerhoff, Constance E ^a   Mullins, David W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CHEMOKINE RECEPTOR CXCR3; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL MIGRATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-8; MALE; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION;

EID: 84925799187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121140     Document Type: Article

References (48)

1. Clark WH, Elder DE, Guerry D, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984 Dec; 15 (12):1147-65. PMID: 6500548
2. Meier F, Satyamoorthy K, Nesbit M, Hsu MY, Schittek B, Garbe C, et al. Molecular events in melanoma development and progression. Front Biosci. 1998 Sep 15; 3:D1005-10. PMID: 9740553
3. Leslie MC, Bar-Eli M. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem. 2005 Jan 1; 94(1):25-38. PMID: 15523674
4. Balch CM, Soong S-J, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004; 54(3):131-49; quiz 182-4. PMID: 15195788
5. American Cancer Society. Cancer Facts and Figures, 2014. Atlanta, Georgia; 2014.
6. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3041-6 doi: 10.1073/pnas.0711741105 PMID: 18287029
7. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 1; 109(3):455-64. PMID: 17200963
8. Smalley KSM, Lioni M, Herlyn M. Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther. 2005 Dec; 5(6):1069-78. PMID: 16336098
9. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010 Jan; 8:67. doi: 10.1186/1479-5876-8-67 PMID: 20630094
10. Long G V, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011 Apr 1; 29 (10):1239-46. doi: 10.1200/JCO.2010.32.4327 PMID: 21343559
11. Lee J-H, Choi J-W, Kim Y-S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011 Apr; 164 (4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x PMID: 21166657
12. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012 Jun 15; 18(12):3242-9. doi: 10.1158/1078-0432.CCR-12-0052 PMID: 22535154
13. Fedorenko I V, Gibney GT, Sondak VK, Smalley KSM. Beyond BRAF: where next for melanoma therapy? Br J Cancer. Cancer Research UK; 2014 Sep 2;
14. Iida J, Wilhelmson KL, Price MA, Wilson CM, Pei D, Furcht LT, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol. 2004 Jan 5; 122 (1):167-76. PMID: 14962105
15. Blackburn JS, Liu I, Coon CI, Brinckerhoff CE. A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene. Nature Publishing Group; 2009 Sep 7; 28(48):4237-48. doi: 10.1038/onc.2009.272 PMID: 19734937
16. Hofmann UB, Westphal JR, Waas ET, Zendman AJ, Cornelissen IM, Ruiter DJ, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer. 1999 Nov; 81(5):774-82. PMID: 10555745
17. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 2000 Jun; 12(6):547-54. PMID: 10843728
18. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006 Sep; 25(3):387-408. PMID: 17043764
19. Ryu B, Kim DS, Deluca AM, Alani RM. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One. Public Library of Science; 2007 Jan 4; 2(7): e594. PMID: 17611626
20. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13. PMID: 9327744
21. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol. 2008 Sep; 9(9):970-80. doi: 10.1038/ni.f.213 PMID: 18711434
22. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. Elsevier Inc.; 2011 Mar 10; 317(5):620-31 doi: 10.1016/j.yexcr.2010.12.017 PMID: 21376175
23. Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep. 2009 Mar; 11 (2):125-31. PMID: 19216844
24. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007 Jul 12; 26(32):4679-88. PMID: 17297455
25. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004 Jun 1; 64(11):4010-7. PMID: 15173015
26. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol. 2007 Jun; 60(6):596-9. PMID: 16522748
27. Lee JT, Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem. 2007 Jul 1; 101(4):862-72. PMID: 17171636
28. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett. 2004; 92(1):171-8.
29. Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE. Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. J Cell Physiol. 2013 Apr; 228(4):773-80 doi: 10.1002/jcp.24225 PMID: 23001823
30. Huntington JT, Shields JM, Der CJ, Wyatt C a, Benbow U, Slingluff CL, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004 Aug 6; 279(32):33168-76. PMID: 15184373
31. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res. 2005 Dec 1; 65(23):11101-8. PMID: 16322260
32. Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 2007 Nov 15; 67(22):10849-58. PMID: 18006830
33. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology. 1999 Jan; 67(1):12-8. PMID: 9873223
34. Johnson M, Li A-R, Liu J, Fu Z, Zhu L, Miao S, et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett. 2007 Jun 15; 17(12):3339-43. PMID: 17448658
35. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 2006 Aug 1; 66(15):7701-7. PMID: 16885372
36. Colvin RA, Campanella GS V, Manice LA, Luster AD. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol. 2006 Aug; 26(15):5838-49. PMID: 16847335
37. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy. Cancer Research. 2012. p. 3928-37.
38. Joseph EW, Pratilas C a, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010 Aug; 107(33):14903-8. doi: 10.1073/pnas.1008990107 PMID: 20668238
39. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010 Jul; 70(13):5518-27. doi: 10.1158/0008-5472.CAN-10-0646 PMID: 20551065
40. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res. 2011 Apr; 17(7):1658-63. doi: 10.1158/1078-0432.CCR-10-0174 PMID: 21447722
41. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun; 364(26):2507-16. doi: 10.1056/NEJMoa1103782 PMID: 21639808
42. Hussein MR, Haemel AK, Sudilovsky O, Wood GS. Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation. J Clin Pathol. 2005 Apr 1; 58(4):389-96. PMID: 15790703
43. Whipple CA, Brinckerhoff CE, Whipple, C.A, Brinckerhoff CE. BRAFV600E melanoma cells secrete factors that activate stromal fibroblasts and enhance tumorigenicity. Br J Cancer. Cancer Research UK; 2014 Oct 14;In press(8):1625-33.
44. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res. 2012 Oct 1; 18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632 PMID: 22850568
45. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 1; 19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630 PMID: 23307859
46. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun. 1990 May 31; 169(1):165-70. PMID: 2190552
47. Suzuki H, Prado GN, Wilkinson N, Navarro J. The N terminus of interleukin-8 (IL-8) receptor confers high affinity binding to human IL-8. J Biol Chem. 1994 Jul 15; 269(28):18263-6. PMID: 7518426
48. Whipple CA, Brinckerhoff CE. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer. Cancer Research UK; 2014 Oct 14; 111(8):1625-33. doi: 10.1038/bjc.2014.452 PMID: 25117819